Naslov
Treatment of tension-type headache with botulinum toxin type-A: long-term follow-up

Autori
Relja, Maja ; Klepac, Nataša

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Eur J Neurol / Francois Boller - Oxford : Blackwell Publishing, 2000, 120-120

Skup
5th Congress of the European Federation of Neurological Societies

Mjesto i datum
Kopenhagen, Danska, 14.10.2000. - 18.10.2000

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Tension-Type Headache; treatment; botulinum toxin

Sažetak
Introduction The possible involvement of sustained contraction of the pericranial muscles in tension-type headache (TTH) prompted us to investigate botulinum toxin type-A (BTX-A) in the treatment of TTH patients. After double-blind, placebocontrolled studeis had shown that BTX-A is significantly better than placebo for symptomatic relief of pain in patients with TTH (ReljaM, Korsic M. Neurology 1999;52(suppl 2):A203;Smuts JA et al. Eur J Neurol 1999;6(suppl 4):S99,we performed longterm follow-up of patients treated eith BTX-A for TTH. Design/Methods:30 patients with TTH, who had been resistent to standard therapy, were enrolled into a 18-month, open-label prospective study. First, the tenderness of pericranial muscles was evalueted by manual palpation in all patients. The patients received BTX-A BTX-A as Botox (dose range 40-95 U, 100 diluted in 1 ml saline) by intramuscular injections into the most tender muscles (frontalis, temporalis, trapezius, sternocleidomastoideus/mastoid process). The clinical outcome was monitored at 4 week intervals using a tenderness assesment score and home diary kept be each patient. Result In total, 28 patients completed the study. There was a sustained improvement in the number of headache-free days over the 18-month period (P<0.001). Headache severity, used as an indirect measure of patinets's quality of life, showed a clear improvement at month 9,12,15 and 18 compared to month 3 and 6. No major adverse events were reported during the study. Conclusions The study concluted that injection of BTX-A are an effective and safe prophylactis treatment for patients with TTH.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA